Brokerages Set Smith & Nephew SNATS, Inc. (NYSE:SNN) PT at $36.25

Smith & Nephew SNATS, Inc. (NYSE:SNN) has earned an average recommendation of “Hold” from the six research firms that are presently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $36.25.

A number of equities research analysts recently weighed in on the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, January 21st. Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday. Royal Bank Of Canada cut Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. Canaccord Genuity Group boosted their target price on Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a report on Thursday. Finally, Kepler Capital Markets raised Smith & Nephew SNATS to a “strong-buy” rating in a research report on Monday, November 17th.

Hedge Funds Weigh In On Smith & Nephew SNATS

A number of hedge funds have recently modified their holdings of SNN. Equity Investment Corp raised its position in Smith & Nephew SNATS by 3.9% in the 4th quarter. Equity Investment Corp now owns 7,502 shares of the medical equipment provider’s stock valued at $246,000 after purchasing an additional 285 shares during the last quarter. Smartleaf Asset Management LLC grew its position in Smith & Nephew SNATS by 13.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,820 shares of the medical equipment provider’s stock worth $93,000 after purchasing an additional 334 shares during the last quarter. Cary Street Partners Financial LLC grew its position in Smith & Nephew SNATS by 1.8% during the 4th quarter. Cary Street Partners Financial LLC now owns 20,255 shares of the medical equipment provider’s stock worth $665,000 after purchasing an additional 365 shares during the last quarter. GAMMA Investing LLC increased its stake in Smith & Nephew SNATS by 11.7% in the third quarter. GAMMA Investing LLC now owns 3,837 shares of the medical equipment provider’s stock valued at $139,000 after purchasing an additional 401 shares during the period. Finally, Versant Capital Management Inc increased its stake in Smith & Nephew SNATS by 5.0% in the third quarter. Versant Capital Management Inc now owns 8,912 shares of the medical equipment provider’s stock valued at $323,000 after purchasing an additional 423 shares during the period. 25.64% of the stock is currently owned by hedge funds and other institutional investors.

Smith & Nephew SNATS Trading Down 1.6%

Shares of NYSE:SNN opened at $34.29 on Friday. The firm has a 50 day simple moving average of $34.43 and a 200-day simple moving average of $34.91. Smith & Nephew SNATS has a twelve month low of $23.91 and a twelve month high of $38.79. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.25 and a current ratio of 2.57.

Smith & Nephew SNATS Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Friday, March 27th will be paid a $0.482 dividend. The ex-dividend date is Friday, March 27th. This represents a yield of 281.0%.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.